Aimmune Therapeutics (AIMT) Investor Meetings with Baird Convey Confidence In Palforzia Launch

Baird analyst Brian Skorney reiterated an Outperform rating and $64.00 price target on Aimmune Therapeutics (NASDAQ: AIMT) after hosting management for a day of investor meetings.

The anlayst stated "When the consensus Palforzia sales were discussed ($55M 2020, $211M 2021), management appeared to be very comfortable where numbers are, even while cautioning that the first year would be largely about gaining formulary access, with year-two sales being multiple of year one sales. The overall enthusiastic commentary reaffirmed the findings from our survey, published earlier this week, indicating the potential for a strong pull-through demand coming from allergists already aware and looking to prescribe Palforzia".

For an analyst ratings summary and ratings history on Aimmune Therapeutics click here. For more ratings news on Aimmune Therapeutics click here.

Shares of Aimmune Therapeutics closed at $24.23 yesterday.

You May Also Be Interested In

• Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)
• BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
• Investec Double Upgrades Alkem Laboratories Ltd (ALKEM:IN) to Buy